Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07077395
PHASE2

Finding Links Between Hot flASHes and CardioVascular Disease

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?

Key Details

Gender

FEMALE

Age Range

40 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-03-01

Completion Date

2029-09

Last Updated

2026-05-20

Healthy Volunteers

No

Interventions

DRUG

elinzanetant - reference formulation

elinzanetant 120 mg daily x 12 weeks

DRUG

placebo

placebo daily x 12 weeks

Locations (2)

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States